Last reviewed · How we verify
IGC-AD1-Active
At a glance
| Generic name | IGC-AD1-Active |
|---|---|
| Also known as | Active |
| Sponsor | IGC Pharma, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial on Agitation in Alzheimer's Dementia (PHASE2)
- Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGC-AD1-Active CI brief — competitive landscape report
- IGC-AD1-Active updates RSS · CI watch RSS
- IGC Pharma, LLC portfolio CI